Metoprolol er succinate 100mg tabs
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that metoprolol succinate extended-release tablets are effective in managing hypertension, reducing cardiovascular events, and improving outcomes in chronic heart failure, with some formulations offering consistent drug release and bioequivalence, while other studies note potential interactions with paroxetine and differences in Tmax between brand and generic products.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Metoprolol ER Succinate 100mg Tablets: A Comprehensive Overview
Introduction to Metoprolol ER Succinate
Metoprolol succinate is a selective β1-adrenergic antagonist widely used in the treatment of hypertension, angina pectoris, and chronic heart failure. The extended-release (ER) formulation of metoprolol succinate is designed to provide consistent β1-blockade over a 24-hour period, making it convenient for once-daily administration .
Formulation and Evaluation of Metoprolol ER Tablets
Bilayer Tablet Design
Metoprolol succinate 100mg tablets can be formulated as bilayer tablets, combining immediate release (IR) and extended release (ER) layers. This design allows for an initial rapid release of the drug followed by a sustained release, ensuring prolonged therapeutic effects. The IR layer typically contains diluents like lactose or microcrystalline cellulose and superdisintegrants such as sodium starch glycolate, while the ER layer uses polymers like HPMC K 100, HPMC K 15M, and HPMC K 4M to control the drug release over 12 hours.
Pharmacokinetics and Bioequivalence
Studies comparing the pharmacokinetics (PK) and bioequivalence of different metoprolol succinate ER formulations have shown that both brand-name and generic versions provide similar therapeutic effects. The area under the concentration-time curve (AUC) and maximum concentration (Cmax) were comparable across different formulations, although the time to maximum concentration (Tmax) varied, which could influence the drug's effects on autonomic balance .
Clinical Efficacy and Safety
Hypertension and Heart Rate Control
Metoprolol succinate ER has been shown to effectively reduce blood pressure (BP) and heart rate (HR) in patients with hypertension. In a double-blind crossover trial, metoprolol succinate ER was more effective than amlodipine in lowering early morning diastolic blood pressure (DBP), heart rate, and rate-pressure product (RPP), which are critical parameters for managing hypertension and reducing myocardial oxygen demand.
Heart Failure Management
In patients with chronic heart failure, metoprolol succinate ER has demonstrated significant benefits. The MERIT-HF trial revealed that metoprolol succinate ER reduced the relative risk of all-cause mortality by 34% and sudden death by 41%, highlighting its efficacy in improving survival rates and reducing hospitalizations.
Combination Therapy
Combining metoprolol succinate ER with other antihypertensive agents, such as diuretics or calcium channel blockers like felodipine, can enhance BP-lowering effects. Studies have shown that low-dose combinations of metoprolol succinate ER and felodipine are as effective as high-dose monotherapy but with better tolerability, making them a viable option for patients requiring combination therapy .
Pharmacokinetic Interactions
The interaction between metoprolol succinate ER and other drugs, such as the CYP2D6 inhibitor paroxetine, can significantly alter metoprolol's pharmacokinetics. Co-administration with paroxetine increases metoprolol plasma concentrations, potentially enhancing β-blockade and affecting cardioselectivity. This interaction underscores the importance of monitoring patients for adverse effects when combining metoprolol with other medications.
Conclusion
Metoprolol succinate ER 100mg tablets are a well-established treatment for hypertension, angina pectoris, and chronic heart failure. The extended-release formulation ensures consistent therapeutic effects with once-daily dosing, improving patient compliance. Clinical studies support its efficacy and safety, both as monotherapy and in combination with other antihypertensive agents. However, potential drug interactions should be carefully managed to optimize therapeutic outcomes.
Sources and full results
Most relevant research papers on this topic
